- Breese EJ, Michie CA, Nicholls SW, Munch SH, Williams CB, Domizio P, et al. Tumor necrosis factor-a-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 1994;106:1455-66.
- Reimund JM, Wittersheim C, Dumont S, Muller CD, Baumann R, Poindron P, et al. Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn's disease. J Clin Immunol 1996;16:144-50.
- Reimund JM, Wittersheim C, Dumont S, Muller CD, Kenney JS, Baumann R, et al. Increased production of tumour necrosis factor-a, interleukin-1ß, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease. Gut 1996;39:684-9.
- Grimm MC, Elsbury SK, Pavli P, Doe WF. Interleukin 8: cells of origin in inflammatory bowel disease. Gut 1996;38:90-8.
- Schreiber S, Nikolaus S, Hampe J, Hamling J, Koop I, Groessner B, et al. Tumour necrosis factor a and interleukin 1ß in relapse of Crohn's disease. Lancet 1999;353:459-61.
- Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337: 1029-35.
- D'haens G, Van Deventer S, Van Hogezand R, Chalmers D, Kothe C, Baert F, et al. Endoscopie and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology 1999; 116:1029-34.
- Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405.
- Eigler A, Sinha B, Hartmann G, Endres S. Taming TNF: strategies to restrain this proin flammatory cytokine. Immunol Today 1997;18:487-92.
- Kunkel SL, Spengler M, May MA, Spengler R, Larrick J, Remick D. Prostaglandin E2 regulates macrophage-derive d tumor necrosis factor gene expression. J Biol Chem 1988263: 5380-4.
- Hartmann G, Bidlingmaier C, Siegmund B, Albrich S, Schulze J, Tschoep K, et al. Specific type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in mice. J Pharmacol Exp Ther 2000;292:22-30.
- Reimund JM, Dumont S, Muller CD, Kenney JS, Kedinger M, Baumann R, et al. In vitro effects of oxpentifylline on inflammatory cytokine release in patients with inflammatory bowel disease. Gut 1997;40:475-80.
- Bauditz J, Haemling J, Ortner M, Lochs H, Raedler A, Schreiber S. Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease. Gut 1997;40:470-4.
- Peterson TC, Davey K. Effect of acute pentoxifylline treatment in an experimental model of colitis. Aliment Pharmacol Ther 1997;11:575-80.
- Gilhar A, Grossman N, Kahanovicz S, Reuveni H, Cohen S, Eitan A. Antiproliferative effect of pentoxifylline on psoriatic and normal epidermis. In vitro and in vivo studies. Acta Derm Venereol 1996;76:437-41.
- Tamou S, Trott KR. Modification of late radiation damage in the rectum of rats by deproteinized calf blood serum (ActoHorm) and pentoxifylline (PTX). Strahlenther Onkol 1994;170:415-20.
- Bianco C, Tortora G, Baldassarre G, Caputo R, Fontanini G, Chine S, et al. 8-Chloro-cyclic AMP inhibits autocrin e and angiogenic growth factor production in human colorectal and breast cancer. Clin Cancer Res 1997;3:439-48.
- Giraud AS. Lessons from genetically engineered animal models. X. Trefoil peptide and EGF receptor/ligand transgenic mice. Am J Physiol Gastrointest Liver Physiol 2000;278:G501-G506.
- Jones MK, Tomikawa M, Mohajer B, Tarnawski AS. Gastrointestinal mucosal regeneration : role of growth factors. Front Biosci 1999;4:303-9.
- Podolsky DK. Regulation of intestinal epithelial proliferation : a few answers, many questions. Am J Physiol 1993;264:G179-G186.
- Podolsky DK. Mucosal immunity and inflammation. V. Innate mechanisms of mucosal defense and repair: the best offense is a good defense. Am J Physiol 1999;277:G495-G499.
- Quaroni A, Wands J, Trelstad RL, Isselbacher KJ. Epithelioid cell cultures from rat small intestine. Characterization by morphologic and immunologie criteria. J Cell Biol 1979;80:248-65.
- Cheng HC, Kemp BE, Pearson RB, Smith AJ, Misconi L, Van Patten SM, et al. A potent synthetic peptide inhibitor of the cAMP-dependent protein kinase. J Biol Chem 1986:261:989-92.
- Knighton DR, Zheng JH, Ten Eyck LF, Xuong NH, Taylor SS, Sowadski JM. Structure of a peptide inhibitor bound to the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science 1991;253:414-20.
- Barnard JA, Warwick GJ, Gold LI. Localization of transforming growth factor ß isoforms in the normal murine small intestine and colon. Gastroenterology 1993;105:67-73.
- Barnard JA, Beauchamp RD, Coffey RJ, Moses HL. Regulation of intestinal epithelial cell growth by transforming growth factor type ß. Proc Natl Acad Sci USA 1989;86:1578-82.
- Koyama SY, Podolsky DK. Differential expression of transforming growth factors a and ß in rat intestinal epithelial cells. J Clin Invest 1989;83:1768-73.
- Alexander CL, Edward M, MacKie RM. Pentoxifylline-induced modulation of melanoma cell growth, adhesion and lymphokine activated killer cell-mediated lysis. Melanoma Res 1999;9:31-9.
- Ventura AC, Bohnke M. Toxicity of pentoxifylline on monolayers of highly proliferative cells of epithelial origin. J Ocul Pharmacol Ther 1999;15:525-35.
- Kaiser GC, Polk DB. Tumor necrosis factor a regulates proliferation in a mouse intestinal cell line. Gastroenterology 1997; 112:1231-40.
- Dionne S, D'Agata ID, Ruemmele FM, Levy E, St-Louis J, Srivastava AK, et al. Tyrosine kinase and MAPK inhibition of TNF-a- and EGF-stimulated IEC-6 cell growth. Biochem Biophys Res Commun 1998;242:146-50.
- Porten CS, Owen G, Hewitt D, Chadwick CA, Hendry H, Lord BI, et al. Stimulation and inhibition of proliferation in the small intestinal crypts of the mouse after in vivo administration of growth factors. Gut 1995;36:864-73.
- Kurokowa M, Lynch K, Podolsky DK. Effects of growth factors on an intestinal epithelial cell line: transforming growth factor ß inhibits proliferation and stimulates differentiation. Biochem Biophys Res Commun 1987;142:775-82.
- Gallucci RM, Simeonova PP, Toriumi W, Luster ML TNF-a regulates transforming growth factor-a expression in regenerating murine liver and isolated hepatocytes. J Immunol 2000; 164: 872-8.
- Chen YM, Wu KD, Tsai TJ, Hsieh BS. Pentoxifylline inhibits PDGF-induced proliferation of and TGF-ß-stimulated collagen synthesis by vascular smooth muscle cells. J Mol Cell Cardiol 1999;31:773-83.
- Peterson TC, Slysz G, Isbrucker R. The inhibitory effect of ursodeoxycholic acid and pentoxifylline on platelet derived growth factor-stimulated proliferation is distinct from an effect by cyclic AMP. Immunopharmacology 1998;39:181-91.
- Pinzani M, Marra F, Caligiuri A, DeFranco R, Gentilini A, Failli P, et al. Inhibition by pentoxifylline of extracellular signalregulated kinase activation by platelet-derived growth factor in hepatic stellate cells. Br J Pharmacol 1996;119:1117-24.
- Wu J, Dent P, Jelinek T, Wolfman A, Weber MJ, Sturgill TW. Inhibition of the EGF-activated MAP kinase signaling pathway by adenosine 3',5'-monophosphate. Science 1993;262:1065-9.
- Cook SJ, McCormick F. Inhibition by cAMP of Ras-dependent activation of Raf. Science 1993;262:1069-72.
- Rhoads JM, Argenzio RA, Chen W, Graves LM, Licato LL, Blikslager AT, et al. Glutamine metabolism stimulates intestinal cell MAPKs by a cAMP-inhibitable, Raf-independent mechanism. Gastroenterology 2000; 118:90-100.
- Coke M, Kanai M, Lynch-Devaney K, Podolsky DK. Rapid mitogen-activale d protein kinase activation by transforming growth factor a in wounded rat intestinal epithelial cells. Gastroenterology 1998;114:697-705.
- Huang F, Sauma S, Yan Z, Friedman E. Colon absorptive epithelial cells lose proliferative response to TGFa as they differentiate. Exp Cell Res 1995;219:8-14.
- Sauma S, Huang F, Winawer S, Friedman E. Colon goblet cells lose proliferative response to TGF-a as they differentiate. Int J Cancer 1995;61:848-53.
- Oliver BL, Sha'afi RI, Hajjar JJ. Transforming growth factor-a increases tyrosine phosphorylation of microtubule-associated protein kinase in a small intestinal crypt cell line (IEC-6). Biochem J 1994;303:455-60.
- Kingsley-Kallesen ML, Kelly D, Rizzino A. Transcriptional regulation of the transforming growth factor-ß2 promoter by cAMP-responsive element-binding protein (CREB) and activating transcription factor-1 (ATF-1) is modulated by protein kinases and the coactivators p300 and CREB-binding protein. J Biol Chem 1999;274:34020-8.
- Levine AE, Lewis LR. Transforming growth factor-ß2 is an autocrine growth inhibitory factor for the MOSER human colon carcinoma cell line. Cancer Lett 1993;68:33-41.
- Saati N, Ravid A, Liberman UA, Koren R. 1,25-dihydroxyvita min D3 and agents that increase intracellular adenosine 3',5'monophosphate synergistically inhibit fibroblast proliferation. In Vitro Cell Dev Biol Anim 1997;33:310-4.
- Desmouliere A, Xu G, Costa AM, Yousef IM, Gabbiani G, Tuchweber B. Effect of pentoxifylline on early proliferation and phenotypic modulation of fibrogenic cells in two rat models of liver fibrosis and on cultured hepatic stellate cells. J Hepatol 1999;30:621-31.
- Hewitson TD, Martic M, Kelynack KJ, Pedagogos E, Becker GJ. Pentoxifylline reduces in vitro renal myofibroblast proliferation and collagen secretion. Am J Nephrol 2000;20:82-8.
- Powell DW, Mifflin RC, Valentich JD, Crowe SE, Saada JI, West AB. Myofibroblasts. I. Paracrine cells important in health and disease. Am J Physiol 1999;277:C1-C9.
- Schaeffer C, Diab-Assef M, Plateroti M, Laurent-Huck F, Reimund JM, Kedinger M, et al. Cytokine gene expression during postnatal small intestinal development: regulation by glucocorticoids. Gut 2000;47:192-8.
- MacDonald TT, Monteleone G, Pender SL Recent developments in the immunology of inflammatory bowel disease. Scand J Immunol 2000;51:2-9.
- Bajaj-Elliott M, Poulsom R, Pender SL, Wathen NC, MacDonald TT. Interactions between stromal cell-derived keratinocyte growth factor and epithelial transforming growth factor in immune-mediated crypt cell hyperplasia. J Clin Invest 1998;102: 1473-80.
- Brauchle M, Madlener M, Wagner AD, Angermeyer K, Lauer U, Hofschneider PH, Gregor M, Werner S. Keratinocyte growth factor is highly overexpressed in inflammatory bowel disease. Am J Pathol 1996;149:521-9.
- Housley RM, Morris CF, Boyle W, Ring B, Biltz R, Tarpley JE, Aukerman SL, Devine PL, Whitehead RH, and Pierce GF. Keratinocyte growth factor induces proliferation of hepatocytes and epithelial cells throughout the rat gastrointestinal tract. J Clin Invest 1994;94:1764-77.
- Arondel Y, Reimund JM, Keravis T, Le Bee A, Duclos B, Baumann R, et al. First characterization of cyclic nucleotide phosphodiesterase s in normal human intestinal mucosa and inflamed mucosa from Crohn's disease (CD) patients. Gastroenterology 1999;116:G3716.
- Schreiber S. Experimental immunomodulatory therapy of inflammatory bowel disease. Neth J Med 1998;53:S24-S31.
- D'Haens GR, Swijsen C, Noman M, Lemmens L, Geboes K, Rutgeerts P. Etanercept (TNF receptor fusion protein, Enbrel®) is effective and well tolerated in active refractory Crohn's disease: results of a single center pilot trial. Gastroenterology 2000;118:A656.
- Jensen MR, Dalum I, Steinaa L, Balchen T, Harris AS, Mouritsen S. Immunization against TNF-a a new approach for the treatment of inflammatory bowel disease. Gastroenterology 2000;! 18: A873.
Scandinavian Journal of Gastroenterology
Volume 37, 2002 - Issue 2